Press Releases Year None20192018201720162015201420132012201120102009 11/12/19 Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019 11/12/19 Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma 11/07/19 Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy 10/30/19 Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update 10/16/19 Exelixis to Release Third Quarter 2019 Financial Results on Wednesday, October 30, 2019 09/25/19 Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 09/03/19 Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 07/31/19 Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update 07/31/19 Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer 07/17/19 Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019 07/15/19 Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors 05/29/19 Exelixis Announces Webcasts of Investor Conference Presentations in June 2019 05/16/19 Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program 05/14/19 Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019 05/13/19 Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan 05/01/19 Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma 05/01/19 Exelixis Announces First Quarter 2019 Financial Results and Provides Corporate Update 04/25/19 Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® (Cabozantinib) for Advanced Renal Cell Carcinoma 04/17/19 Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019 04/05/19 Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019 03/05/19 Exelixis Announces Webcasts of Investor Conference Presentations in March 02/12/19 Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update 02/12/19 Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts 02/07/19 Exelixis to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 on February 14, 2019 01/29/19 Exelixis to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 12, 2019 01/14/19 Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma 01/08/19 Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets for the Treatment of Hypertension in Japan
